Pierre Fabre vs. Rubicon: Propranolol Patent Infringement Settled with Injunction
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Pierre Fabre Medicament SAS et al. v. Rubicon Research Private Limited |
| Case Number | 1:24-cv-00811 (D. Del.) |
| Court | U.S. District Court for the District of Delaware |
| Duration | July 2024 – Jan 2026 1 year 6 months |
| Outcome | Plaintiff Win — Consent Judgment & Injunction |
| Patents at Issue | |
| Accused Products | Rubicon’s ANDA No. 219574 (Generic Propranolol HCl Oral Solution) |
Case Overview
The Parties
⚖️ Plaintiff
French pharmaceutical company holding an established IP portfolio in dermatology and specialty pharmaceuticals, including HEMANGEOL.
🛡️ Defendant
Indian pharmaceutical company specializing in generic drug formulations, which filed ANDA No. 219574 for a generic HEMANGEOL.
Patents at Issue
This Hatch-Waxman case involved two Orange Book-listed patents covering propranolol hydrochloride, the active ingredient in HEMANGEOL. These patents protect formulations or methods related to the pharmaceutical composition.
- • U.S. Patent No. 8,338,489 — Covering formulations or methods related to propranolol-based pharmaceutical compositions.
- • U.S. Patent No. 8,987,262 — Similarly directed to propranolol compositions or treatment methods.
Developing a similar pharmaceutical formulation?
Check if your product might infringe these or related patents before seeking FDA approval.
The Verdict & Legal Analysis
Outcome
The case concluded via **consent judgment and permanent injunction** entered January 15, 2026. The parties stipulated to the validity, enforceability, and infringement of both U.S. Patent Nos. 8,338,489 and 8,987,262 by Rubicon’s proposed ANDA product. Rubicon is permanently enjoined from commercializing the accused product in the U.S., subject to terms of an undisclosed settlement agreement.
Key Legal Issues
The infringement action arose under the Hatch-Waxman Act framework, where Rubicon’s ANDA filing with a Paragraph IV certification constituted a statutory act of infringement under 35 U.S.C. § 271(e)(2). By proceeding to consent judgment with explicit validity and infringement acknowledgment, Rubicon effectively conceded both issues, a meaningful outcome for Pierre Fabre. The Orange Book-listed patents with this consent-judgment-backed validity finding present a significantly higher litigation risk for future generic challengers.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical generic development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View related patents in this therapeutic space
- See which companies are most active in similar formulations
- Understand claim construction patterns for pharmaceutical patents
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Propranolol oral solution formulations
2 Orange Book Patents
Confirmed valid & infringed
Hatch-Waxman Precedent
Stronger position for patent holder
✅ Key Takeaways
Consent judgments with explicit validity and infringement findings provide stronger enforcement leverage in Hatch-Waxman cases.
Search related case law →Delaware remains a premier venue for pharmaceutical ANDA patent litigation due to its experienced judiciary.
Explore precedents →Frequently Asked Questions
U.S. Patent Nos. 8,338,489 and 8,987,262, both Orange Book-listed and covering propranolol hydrochloride compositions used in HEMANGEOL.
Rubicon’s ANDA No. 219574 for a generic propranolol hydrochloride oral solution constituted statutory infringement under 35 U.S.C. § 271(e)(2); the consent judgment explicitly confirmed infringement and validity.
Future ANDA challengers to HEMANGEOL face a consent-judgment-backed validity record, raising the evidentiary bar for any invalidity challenge to these two patents.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER Case Lookup – Case No. 1:24-cv-00811
- U.S. Patent and Trademark Office — Patent Full-Text Database
- FDA Orange Book – ANDA Search
- Cornell Legal Information Institute — 35 U.S.C. § 271(e)(2)
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.